[Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes]

Med Clin (Barc). 2011 Jan:136 Suppl 1:34-7. doi: 10.1016/S0025-7753(11)70007-0.
[Article in Spanish]

Abstract

Canakinumab is a fully human monoclonal antibody targeted at IL-1β which has shown to be effective in the control the symptoms of patients affected by CAPS and other autoinflammatory diseases. Its effect is rapid and sustained. In clinical trials conducted up until now, the most common adverse effects reported with the use of this drug have been different types of infections, migraines and vertigo.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Carrier Proteins / genetics
  • Carrier Proteins / physiology
  • Clinical Trials, Phase III as Topic / statistics & numerical data
  • Cryopyrin-Associated Periodic Syndromes / drug therapy
  • Disease Susceptibility
  • Half-Life
  • Headache / chemically induced
  • Humans
  • Infections / etiology
  • Inflammation / drug therapy*
  • Inflammation / immunology
  • Interleukin-1beta / antagonists & inhibitors*
  • Interleukin-1beta / biosynthesis
  • Interleukin-1beta / immunology
  • Multicenter Studies as Topic / statistics & numerical data
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Up-Regulation
  • Vertigo / chemically induced

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Carrier Proteins
  • Interleukin-1beta
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human
  • canakinumab